Last reviewed 2026-04-20 · How we verify

Jincaopian Tablets high dose

Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2 active Small molecule Quality 3/100

Jincaopian Tablets high dose is a Small molecule drug developed by Beijing Konruns Pharmaceutical Co., Ltd.. It is currently in Phase 2 development. Also known as: ZY5301.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Jincaopian Tablets high dose
Also known as	ZY5301
Sponsor	Beijing Konruns Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effect of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Jincaopian Tablets high dose CI brief — competitive landscape report
Jincaopian Tablets high dose updates RSS · CI watch RSS
Beijing Konruns Pharmaceutical Co., Ltd. portfolio CI

Frequently asked questions about Jincaopian Tablets high dose

What is Jincaopian Tablets high dose?

Jincaopian Tablets high dose is a Small molecule drug developed by Beijing Konruns Pharmaceutical Co., Ltd..

Who makes Jincaopian Tablets high dose?

Jincaopian Tablets high dose is developed by Beijing Konruns Pharmaceutical Co., Ltd. (see full Beijing Konruns Pharmaceutical Co., Ltd. pipeline at /company/beijing-konruns-pharmaceutical-co-ltd).

Is Jincaopian Tablets high dose also known as anything else?

Jincaopian Tablets high dose is also known as ZY5301.

What development phase is Jincaopian Tablets high dose in?

Jincaopian Tablets high dose is in Phase 2.

Manufacturer: Beijing Konruns Pharmaceutical Co., Ltd. — full pipeline
Also known as: ZY5301

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing